answer the attached question paper as a 10marks DNB answer so that i can write in my exam
| Q | Topic | Must-Write Points |
|---|---|---|
| Q1a | Wound Healing (5M) | 4 phases + local vs systemic factors table + 5 ways to improve (NPWT, nutrition, glucose, TXA, moist dressing) |
| Q1b | Cricothyrotomy (5M) | CICO indication + CTM anatomy + 8-step technique + complications (subglottic stenosis) |
| Q2 | Nuclear Medicine (4+3+3) | 8 modalities table + Ga-68 DOTATATE for paraganglioma + Tc-99m MIBI double phase for parathyroid |
| Q3 | Hemorrhagic Shock (3+3+2+2) | ATLS Class I-IV table + DCR (1:1:1) + TXA + pRBC 1 unit = +1g Hb + FFP contains all factors |
| Q4a | Cystic Hygroma (5M) | OK-432 sclerotherapy + Sirolimus + Surgery + EXIT procedure + Turner/Down associations |
| Q4b | CBNAAT (5M) | PCR detects MTB + RIF resistance in 2 hrs + sensitivity 80-90% for LN TB + NTEP first-line |
| Q5a | Branchial Anomalies (4M) | Cervical sinus of His + Type I/II/III/IV 2nd branchial cleft (Bailey classification) |
| Q5b | Type 1 Branchial Cleft (3+3) | Work Type I vs II + parallel to EAC + facial nerve risk + facial nerve monitoring mandatory |
| Q6a | Thyroid Ophthalmopathy (5M) | NOSPECS + CAS + IV methylprednisolone + Teprotumumab + Surgery sequence: decompress→strabismus→lids |
| Q6b | Central Neck Dissection (5M) | Level VI + therapeutic vs prophylactic + ATA 2015 guidelines + parathyroid autotransplantation |
| Q7 | Stereotactic Radiation (3+4+3) | SRS 12-13 Gy + 93-97% control at 10yr + pseudoprogression 30% + complications: facial palsy <1%, hearing loss 25-50% |
| Q8 | VSB vs BAHA (2+2+3+3) | FMT drives ossicles/RW vs BAHA bone conduction through skull + RW application for SNHL |
| Q9a | Milan System (5M) | 6 categories + ROM values (I=25%, II<10%, IVa<5%, IVb=35%, V=60%, VI=90%) |
| Q9b | Facial Nerve Landmarks (5M) | Tragal pointer (1cm deep, inferior, medial) + Post digastric + Tympanomastoid fissure + NIM mandatory |
| Q10 | Hearing Loss Genes + GT (4+4) | GJB2/Connexin 26 most common + OTOF = auditory neuropathy + 2024 OTOF gene therapy success + AAV vector |